Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CCND1 Antibodies

The Cyclin D1 (CD1) protein is a crucial regulator of cell cycle progression, encoded by the CCND1 gene on chromosome 11q13. It consists of 295 amino acids, resulting in a molecular weight of approximately 34 kDa. CD1 undergoes various post-translational modifications, including phosphorylation, glycosylation, and ubiquitination, which dynamically regulate its activity. Primarily an intracellular protein, CD1 functions as a key component of the cell cycle machinery, facilitating the transition from the G1 phase to the S phase by activating cyclin-dependent kinases (CDKs) and is a known cyclin and mantle cell marker. 

Its expression is observed in various organs and tissues, notably in proliferating breast, lung, colon, and prostate cells. Extracellular signals, such as growth factors and mitogens, tightly regulate the expression of CD1. The dysregulation of CD1 expression or mutations in the CCND1 gene have been associated with numerous cancers, including breast, lung, and esophageal cancers. 

Cyclin D1 expression serves as a diagnostic and prognostic marker in certain malignancies, aiding in patient management and treatment decisions. Detecting Cyclin D1 expression in tumor tissues can aid in the classification of certain malignancies, particularly in hematological and solid tumors. CD1 overexpression is also a hallmark of mantle cell lymphoma (MCL), and its detection in lymph node biopsies can help differentiate MCL from other types of non-Hodgkin lymphomas. Similarly, Cyclin D1 expression in breast cancer tissues may indicate a specific subtype, such as the luminal B subtype, which has implications for treatment selection. Regarding prognosis, CD1 expression in tumors has been correlated with aggressive tumor behavior, increased risk of disease recurrence, and poorer overall survival in breast and esophageal cancers. On the other hand, low or absent CD1 expression may indicate a more favorable prognosis in certain malignancies. 

NeoBiotechnologies offers a variety of antibodies against CD1 that have been validated for ELISA, flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting, as well as HuProt-validated option. Additionally, we hold exclusive rights to CD1 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/gene-name/ccnd1/].


G1/S-specific cyclin-D1, B-cell lymphoma 1 protein, BCL-1 oncogene, PRAD1 oncogene, B cell CLL/lymphoma 1, B cell leukemia 1, B-cell lymphoma 1 protein, BCL-1 oncogene, CCND1 protein, CCND1/FSTL3 fusion gene, CCND1/IGHG1 fusion gene CCND1/IGLC1 fusion gene, CCND1/PTH fusion gene, cD1, Cyl 1, G1/S-specific cyclin-D1, Parathyroid adenomatosis 1, PRAD1 oncogene

Research Areas

Breast Cancer, Cancer, Cardiovascular, Immunology, AKT Signaling, Bladder Cancer, Colon Cancer, Cytokine Signaling, Infectious Disease, Lung Cancer, Nuclear Marker, Signal Transduction, Transcription Factors

Showing all 14 results


Showing all 14 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.